Recent Additions

AZT-01 by Azitra
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:14 (1 month ago)
Date last modified: 2019/09/12 15:14 (1 month ago)
Known funding amount: N/A
Funding types: Government + Private Funding
Industry: Health + Medical
Market status: Early Stage Concept
Organization type(s): Public Company
Product categories: Personal Care (Topical)
Production process: N/A
Source: SynBio Database
Trading symbol: N/A
Value chain stage: Finished Product
AZT-02 by Azitra
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:14 (1 month ago)
Date last modified: 2019/09/12 15:14 (1 month ago)
Known funding amount: N/A
Funding types: Government + Private Funding
Industry: Health + Medical
Market status: Early Stage Concept
Organization type(s): Public Company
Product categories: Personal Care (Topical)
Production process: N/A
Source: SynBio Database
Trading symbol: N/A
Value chain stage: Finished Product
AZT-05 by Azitra
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:14 (1 month ago)
Date last modified: 2019/09/12 15:14 (1 month ago)
Known funding amount: N/A
Funding types: Government + Private Funding
Industry: Health + Medical
Market status: Early Stage Concept
Organization type(s): Public Company
Product categories: Personal Care (Topical)
Production process: N/A
Source: SynBio Database
Trading symbol: N/A
Value chain stage: Finished Product
ActoBiotics: AG013 (Oral Mucositis) by Actobio Therapeutics
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (1 month ago)
Date last modified: 2019/09/12 15:12 (1 month ago)
Known funding amount: N/A
Funding types: Government + Shareholder Investment
Industry: Medical
Market status: Under Development
Organization type(s): Private Company
Product categories: Personal Care (Topical) + Medicine
Production process: N/A
Source: Web search
Trading symbol: XON (NASDAQ)
Value chain stage: Finished Product
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (1 month ago)
Date last modified: 2019/09/12 15:12 (1 month ago)
Known funding amount: N/A
Funding types: Private Funding + Shareholder Investment
Industry: Medical
Market status: Early Stage Concept
Organization type(s): Private Company
Product categories: Personal Care (Topical)
Production process: N/A
Source: Web search
Trading symbol: XON (NASDAQ)
Value chain stage: Finished Product
ActoBiotics: AG017 (Celiac Disease) by Actobio Therapeutics
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (1 month ago)
Date last modified: 2019/09/16 16:28 (4 weeks ago)
Known funding amount: N/A
Funding types: Private Funding + Shareholder Investment
Industry: Health + Medical
Market status: Early Stage Concept
Organization type(s): Private Company
Product categories: Personal Care (Ingested)
Production process: N/A
Source: Web search
Trading symbol: XON (NASDAQ)
Value chain stage: Finished Product
ActoBiotics: AG019 (Type 1 Diabetes) by Actobio Therapeutics
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (1 month ago)
Date last modified: 2019/09/12 15:12 (1 month ago)
Known funding amount: N/A
Funding types: Private Funding + Shareholder Investment
Industry: Medical
Market status: Under Development
Organization type(s): Private Company
Product categories: Medical Treatment + Medicine
Production process: N/A
Source: Web search
Trading symbol: XON (NASDAQ)
Value chain stage: Finished Product
ActoBiotics: AG018 (Rhinosinusitus) by Actobio Therapeutics
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (1 month ago)
Date last modified: 2019/09/12 15:12 (1 month ago)
Known funding amount: N/A
Funding types: Private Funding + Shareholder Investment
Industry: Medical
Market status: Under Development
Organization type(s): Private Company
Product categories: Personal Care (Topical)
Production process: N/A
Source: Web search
Trading symbol: XON (NASDAQ)
Value chain stage: Finished Product
OG716: Lantibiotics by Oakbio + Oragenics
Biotech components: Molecule
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (1 month ago)
Date last modified: 2019/09/12 15:16 (1 month ago)
Known funding amount: N/A
Funding types: Private Funding + Shareholder Investment
Industry: Medical
Market status: Early Stage Concept
Organization type(s): Private Company
Product categories: Medicine
Production process: N/A
Source: Web search
Trading symbol: N/A
Value chain stage: Finished Product
Non-browning Lettuce by Intrexon
Biotech components: Gene Editing
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (1 month ago)
Date last modified: 2019/09/12 15:12 (1 month ago)
Known funding amount: N/A
Funding types: Shareholder Investment
Industry: Food & Agriculture
Market status: Early Stage Concept
Organization type(s): Public Company
Product categories: Food + Plant
Production process: N/A
Source: N/A
Trading symbol: N/A
Value chain stage: Finished Product